Project Grant R01CA301050
Award Date
4/17/25
Completion Date
3/31/30
Dollars Obligated
$685K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
The National Cancer Institute (NCI) awarded a $1,343,188 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at understanding the development of drug resistance in cancer. The 5-year project, which commenced on June 15, 2024, will utilize a mouse model of squamous cell carcinoma to investigate the molecular mechanisms underlying the emergence of highly heterogeneous, drug-resistant...
The federal Project Grant award of $953,982 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support research by The Trustees of Columbia University in the City of New York to investigate mechanisms of tumor plasticity in human bladder cancer. The research aims to elucidate the mechanistic basis for the phenotypic switch between luminal and basal subtypes of bladder tumors, which is associated with tumor progression and invasive...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,224,644.00 to the Icahn School of Medicine at Mount Sinai to conduct research focused on dissecting the role of the B7-H4 protein and its interactions with the TGF-beta pathway in the development and progression of intrahepatic cholangiocarcinoma (CCA), a deadly form of liver cancer. The research aims to: 1) Elucidate the molecular mechanisms by which B7-H4 promotes CCA cell...
The National Cancer Institute (NCI) awarded a $560,297 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Icahn School of Medicine at Mount Sinai. The grant, with a project period from September 1, 2024 to August 31, 2029, will fund research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The research aims to determine the molecular drivers of the ONFSCS and their role in CRC progression and treatment resistance, as well as...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $684,367 to support research aimed at identifying intratumoral microbiome profiles and spatial immune signatures that can predict response to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer. The project, led by researchers at Baylor College of Medicine, will analyze pre-treatment tumor samples from three independent cohorts (totaling...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $107,948 to the Icahn School of Medicine at Mount Sinai to investigate the role of the interferon gamma (IFNγ) signaling pathway in lung cancer and tumor immunity. The research project aims to: 1) Examine how knocking out the SOCS1 gene, a negative regulator of the IFNγ pathway, impacts the tumor microenvironment and response to immune checkpoint blockade therapy in a mouse model of...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a novel bladder cancer diagnostic assay called BCDX. The BCDX assay uses advanced nanotechnology to detect a comprehensive panel of 12 different biomarkers, including proteins, miRNAs, mRNAs, and lncRNAs, directly from a urine sample. The goal of this $821,797 award, with a project period from September 2024 to August 2026, is...
This Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) totaling $680,334 will support research to elucidate the molecular mechanisms driving age-associated inflammation and pathogenic myelopoiesis, which contribute to increased cancer risk and progression in older individuals. The primary awardee, the Icahn School of Medicine at Mount Sinai, will conduct high-dimensional profiling of tumors from early-stage lung cancer patients, perform multi-omics...
This Project Grant award of $695,797 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports a multi-disciplinary research program focused on discovering new tumor antigens and T-cell receptors (TCRs) for the treatment of platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The award aims to leverage innovative multi-omic technologies, including long-read RNA sequencing and immunopeptidomics, to uncover cancer-specific protein isoforms that can...